LONDON, June 26 /CNW/ - Duke University Medical Center has licensed
ALPHADAS(R) Logos Technologies electronic data capture (EDC) software to
accelerate and streamline its early-phase clinical trials and to enable
physicians to follow patients more closely.
Researchers at Duke, which will become the first academic medical center
in the country to use the ALPHADAS system, believe the technology has the
potential to be a more accurate, real-time system that may improve the safety
of clinical trial participants and contribute to more timely development of
The agreement was announced today at the 44th annual Drug Information
Association meeting in Boston.
"We will be using this innovative system in our two clinical research
units as well as in our new, 30-bed Phase I Duke Clinical Research Unit
(DCRU)," said Robert M. Califf, MD, director of the Duke Translational
Medicine Institute and vice chancellor for clinical research at the Duke
University School of Medicine. "The Phase I trial program here will become the
hub of our efforts in translational science. It's where we will do some of our
most exciting work, which will focus on proof-of-concept studies evaluating
the impact of new therapies on human systems biology."
Duke will pay for the project through support from the Clinical and
Translational Science Award, a five-year, $53 million grant from the National
Institutes of Health awarded to Duke in 2006. The grant is intended to
transform how clinical and translational research is conducted, and enabling
researchers to develop new treatments faster and deliver them to patients more
efficiently and quickly.
Barry Mangum, PharmD, FCP, director of clinical pharmacology for the DCRU
and associate clinical professor of clinical pharmacology at Duke University
Medical Center, says the proprietary ALPHADAS software will run on the DCRU's
computer system to capture, integrate and report on clinical data in
"In using this system, we will be able to capture and enter specific
patient-safety data necessary for accurate adverse-event reporting, while also
collecting other key data components that will aid us in designing a dose and
dosing interval for that specific subject population," he said.
Logos Technologies has been providing early phase EDC and clinical site
automation tools to the pharmaceutical industry for over 10 years, "We look
forward to this opportunity to work with Duke, a leading and world class
academic medical center," said Giles Wilson, BEng, co-founder of Logos
Technologies. "The partnership will help us achieve our mission to reduce the
development time of life-saving and life-enhancing drugs.
"We very much look forward to working with Logos Technologies to
implement ALPHADAS at Duke" said Steve Woody, Associate CIO for Translational
and Clinical Research for Duke Medicine. "We evaluated the market and believe
ALPHADAS to be the best fit for our needs in developing a first-class
proof-of-concept global effort."
For further information:
For further information: Logos Technologies,
http://www.logostechnologies.com; Duke Medicine News and Communications,
email@example.com, (919) 660-1301, http://dukemednews.org